Adragos Pharma, a global contract development and manufacturing organization (CDMO), has appointed Konstantinos (Kostas) Rengis as its new Chief Executive Officer, succeeding Dr. Andreas Raabe, who founded the company and led it over the past six years.

Raabe will remain a shareholder of Adragos and continue to support the company while shifting his focus from daily operations toward investment activities and advisory support.

About Konstantinos Rengis

Rengis brings extensive international leadership experience across pharmaceutical manufacturing, R&D and CDMO operations, with a strong track record in leading complex multi-site organizations across Europe, North America, Latin America and Asia. Most recently, he served as Group CEO of FAMAR, where he led a significant transformation of the business and accelerated operational and commercial performance.

“My focus at Adragos is to build on the strong foundations already in place and continue developing a reliable, high-performing organization for our customers, employees, partners and shareholders, working closely with the Board and leadership teams across the organization,” Rengis remarked. “This next phase will focus on operational execution, consistent delivery, integration of capabilities across the network, and the continued development of our manufacturing, R&D and commercial activities.”

The transition has been structured to ensure full continuity for customers, partners and employees, with a defined handover period to support the continued reliability of Adragos as a long-term partner to its stakeholders.